Last updated on July 2018

A Study in Healthy Volunteers and Patients With Chronic Hepatitis B

Brief description of study

This two-part, Phase 1 protocol will be the first clinical study of ABI-H0731. Part I will be a Phase 1a dose-ranging assessment of ABI-H0731 in healthy adult volunteers. If the dose-related safety, tolerability and pharmacokinetics (PK) of ABI-H0731 in human volunteers are deemed satisfactory, then the study will advance to Part II, a Phase 1b dose-ranging assessment of ABI-H0731 in non-cirrhotic, CHB patients.

Clinical Study Identifier: NCT02908191

Contact Investigators or Research Sites near you

Start Over

Assembly Biosiences

Auckland, New Zealand

Assembly Biosiences

Hamilton, New Zealand